- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Kailera Aims For Up To $533M+ Nasdaq IPO To Support China-Derived Obesity Drug Pipeline
Biotech firm targets major public offering to fund late-stage trials for lead obesity therapy
Apr. 14, 2026 at 3:54pm
Got story updates? Submit your updates here. ›
A new biotech IPO aims to fund late-stage trials for an innovative obesity drug derived from Chinese research.Waltham TodayKailera Therapeutics, a Massachusetts-based biotech company, is planning a Nasdaq IPO that could raise up to $533 million. The company has outlined terms for 33.3 million shares priced between $14 and $16 per share, with the goal of funding late-stage clinical trials for its lead obesity drug candidate, ribupatide, which was originally developed by Chinese pharmaceutical firm Jiangsu Hengrui.
Why it matters
Kailera's planned IPO represents one of the largest biotech listings expected this year, underscoring investor appetite for innovative obesity treatments as the global prevalence of the condition continues to rise. The company's pipeline, built on assets licensed from a Chinese drugmaker, also highlights the growing cross-border collaborations in the pharmaceutical industry.
The details
Kailera was launched in 2024 with ex-China rights to four obesity drug candidates originally developed by Jiangsu Hengrui Pharmaceuticals. Its lead asset, ribupatide (KAI-9531), is a once-weekly injectable GLP-1/GIP dual agonist now in global Phase 3 trials, which produced mean weight loss of nearly 18% at 48 weeks in a Phase 3 study in China. The company is also advancing an oral version of ribupatide that delivered up to about 12%-12.1% average weight loss over 26 weeks in a mid-stage Chinese trial earlier this year. Additionally, Kailera's pipeline includes another oral GLP-1, KAI-7535 (already in Phase 3 in China), and a 'tri-agonist' injectable that is expected to enter human trials later this year.
- Kailera was launched in 2024 with ex-China rights to four obesity drug candidates.
- Kailera's lead asset, ribupatide, produced mean weight loss of nearly 18% at 48 weeks in a Phase 3 study in China.
- Kailera's oral version of ribupatide delivered up to about 12%-12.1% average weight loss over 26 weeks in a mid-stage Chinese trial earlier this year.
- Kailera's 'tri-agonist' injectable is expected to enter human trials later this year.
The players
Kailera Therapeutics
A Massachusetts-based biotech company that is planning a Nasdaq IPO to raise up to $533 million to fund late-stage clinical trials for its obesity drug pipeline.
Jiangsu Hengrui Pharmaceuticals
A Chinese pharmaceutical firm that originally developed the obesity drug candidates that Kailera has licensed the ex-China rights to.
What’s next
If development stays on track, management has suggested Kailera's lead obesity therapy, ribupatide, could reach the market as early as 2029, positioning the company as a later-wave player in a still-expanding GLP-1 market.
The takeaway
Kailera's planned IPO represents a high-risk, late-cycle obesity bet for investors, as the company seeks to capitalize on the growing demand for innovative weight loss treatments. The success of its pipeline, built on assets licensed from a Chinese drugmaker, will depend on confirming robust Phase 3 data, navigating regulatory review, and carving out a share in the increasingly crowded GLP-1 space.
